Importantly, despite the limitations of the study, including also the small size (affecting the statistical power) of the two matched cohorts of MET-positive and MET-negative MM patients, our data indicate that MET-protein overexpression was associated with lower RR to standard platinum-pemetrexed chemotherapy for MM, while no significant difference in median PFS and median OS after standard chemotherapy was observed between the two groups. This evidence concerns the gene MET and Miyoshi myopathy.